Mangoceuticals, INC 8-K filings

Mangoceuticals, Inc. stockholders approved amendments to the 2022 Equity Incentive Plan and a reverse stock split at a special meeting on March 25, 2024.

Mangoceuticals has been granted an extension by Nasdaq until April 29, 2024, to regain compliance with the minimum stockholders' equity requirement for continued listing.

Mangoceuticals issued a warrant to Boustead Securities for 42,000 shares at $0.375 per share following the full exercise of an over-allotment option in their recent public offering.